更新于：2024-06-22
Fluticasone propionate/Salmeterol xinafoate
丙酸氟替卡松/昔萘酸沙美特罗
更新于：2024-06-22
概要
基本信息
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)临床1期 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C25H31F3O5S |
InChIKeyWMWTYOKRWGGJOA-CENSZEJFSA-N |
CAS号80474-14-2 |
查看全部结构式(2)
关联
255
项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的临床试验沙美特罗替卡松粉吸入剂在健康人空腹状态下的生物等效性试验
Double-Blinded, Placebo-Controlled, Randomized, 2 Period, Crossover Phase 1/2a Study Testing Safety/Efficacy of Advair HFA (Salmeterol, Fluticasone) in Resting & Exercising Healthy & High Altitude Pulmonary Edema (HAPE) Predisposed Subjects
沙美特罗替卡松吸入粉雾剂在健康受试者中的空腹、单中心、随机、开放、单次给药、两制剂、两序列、两周期、交叉生物等效性试验。
100 项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的临床结果
登录后查看更多信息
100 项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的转化医学
登录后查看更多信息
100 项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的专利（医药）
登录后查看更多信息
636
项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的文献（医药）2024-03-01Journal of hazardous materials
Specific resistance and adsorption performance of acid-modified fly ash for escaped ammonia in flue gas
Article
作者: Zhang, Jiahao ; Qi, Liqiang ; Wang, Wen
Escaped ammonia emission following Selective Catalytic Reduction denitrification significantly influences subsequent flue gas treatment processes. This study investigates the adsorption capabilities of acid-modified fly ash concerning escaped ammonia (NH3) and its consequential impact on specific resistance. Furthermore, the adsorption mechanism of acid-modified fly ash on NH3 was explained. Acid activation facilitated the dissolution of a portion of Fe and Al constituents within the fly ash, the contents of Fe and Al in SFA decrease by 4.91% and 5.64%, respectively. In addition, the specific surface area and porosity of fly ash are obviously improved. The specific surface areas of HFA and SFA increased from 1.83 (OFA) to 4.69 and 7.71 m2/g, respectively. Adsorption kinetics adhered to the pseudo-first-order model. SFA showed the best adsorption performance, with NH3 adsorption up to 10.65 mg/g, which was 4.27 times higher than OFA. The creation of a surface liquid film during NH3 adsorption led to decreased specific resistance values across all fly ash samples after-adsorption. The highest specific resistance values recorded for original fly ash (OFA), hydrochloric acid-modified fly ash (HFA) and sulfuric acid-modified fly ash (SFA) were 6.21 × 1012, 3.37 × 1011 and 5.02 × 1010 Ω·cm, respectively. Sulfuric acid activation makes fly ash have stronger adsorption capacity for escaping ammonia, and SFA maintains good specific resistance characteristics, which has good application prospects in electrostatic precipitation and air pollution control.
2024-02-01The Science of the total environment
Plant testing with hemp and miscanthus to assess phytomanagement options including biostimulants and mycorrhizae on a metal-contaminated soil to provide biomass for sustainable biofuel production
Article
作者: Francin, Romain ; Mench, Michel ; Papazoglou, Eleni G ; Waterlot, Christophe ; Burges, Aritz ; Manu, James ; Ofori-Agyemang, Felix ; Laloge, Roman ; Tisserant, Benoît ; Alexopoulou, Efthymia ; Sahraoui, Anissa Lounès-Hadj ; Oustrière, Nadège
The need of biofuels from biomass, including sustainable aviation fuel, without using agricultural land dedicated to food crops, is in constant demand. Strategies to intensify biomass production using mycorrhizal fungi, biostimulants and their combinations could be solutions for improving the cultivation of lignocellulosic plants but still lack well-established validation on metal-contaminated soils. This study aimed to assess the yield of Miscanthus x giganteus J.M. Greef & Deuter and Cannabis sativa L. grown on a metal-contaminated agricultural soil (11 mg Cd, 536 mg Pb and 955 mg Zn kg-1) amended with biostimulants and/or arbuscular mycorrhizal fungi, and the shoot Cd, Pb and Zn uptake. A pot trial was carried out with soil collected from a field near a former Pb/Zn smelter in France and six treatments: control (C), protein hydrolysate (a mixture of peptides and amino acids, PH), humic/fulvic acids (HFA), arbuscular mycorrhizae fungi (AMF), PH combined with AMF (PHxAMF), and HFA combined with AMF (HFAxAMF). Metal concentrations in the soil pore water (SPW), pH and electrical conductivity were measured over time. Miscanthus and hemp shoots were harvested on day 90. Both PH and PHxAMF treatments increased SPW Cd, Pb, and Zn concentrations (e.g. by 26, 1.9, and 22.9 times for miscanthus and 9.7, 4.7, and 19.3 times for hemp in the PH and PHxAMF treatments as compared to the control one, respectively). This led to phytotoxicity and reduced shoot yield for miscanthus. Conversely, HFA and HFAxAMF treatments decreased SPW Cd and Zn concentrations, increasing shoot yields for hemp and miscanthus. Shoot Cd, Pb, and Zn uptakes peaked for PH and PHxAMF hemp plants (in μg plant-1, Cd: 310-334, Pb: 34-38, and Zn: 232-309 for PHxAMF and PH, respectively), while lowest values occurred for PH miscanthus plants mainly due to low shoot yield. Overall, this study suggested that humic/fulvic acids can be an effective biostimulant for increasing shoot biomass production in a metal-contaminated soil. These results warrant further investigations of the HFAxAMF in field trials.
2023-12-01Pulmonary pharmacology & therapeutics
Relative bioavailability of budesonide/glycopyrrolate/formoterol fumarate triple therapy delivered using next generation propellants with low global warming potential
Article
作者: Madriaga, Jonathan ; Collison, Kathryn ; Archbell, James ; Mei, Jie ; Aurivillius, Magnus ; Bednarczyk, Artur ; Surujbally, Raulin ; Kokot, Marek ; Gillen, Michael ; Joshi, Vidya
INTRODUCTION:
The climate crisis poses an immediate threat to human health and well-being, demanding urgent adaptions across sectors, including healthcare. The development of pressurized metered dose inhalers (MDIs) with greater sensitivity to the climate emergency using novel propellants with lower global warming potentials (GWPs), but comparable pharmacokinetic (PK) parameters to currently marketed MDIs, is a vital step toward reducing the impact of healthcare for respiratory disorders on climate change. This study evaluated the relative bioavailabilities of the individual components of a fixed-dose combination of budesonide/glycopyrrolate/formoterol fumarate (BGF) 160/9/4.8 μg per actuation between three different propellant formulations.
METHODS:
Healthy male participants (aged 18-60 years) were randomized into a single-blind, three-period, single-dose, single-center, crossover study (NCT04600505). The PK and safety and tolerability profiles of BGF MDI formulated with two novel propellants with low GWP (hydrofluoroolefin-1234ze [HFO]; hydrofluorocarbon-152a [HFC]) were compared with BGF MDI formulated with the propellant used in the currently marketed reference product (hydrofluoroalkane-134a [HFA]). The study included a screening period, three treatment periods (with 3- to 7-day washout periods between each dose), and a follow-up. The primary PK parameters assessed were maximum observed plasma concentration (Cmax), area under the plasma concentration curve (AUC) from time zero extrapolated to infinity (AUCinf), and AUC from time zero to the time of the last quantifiable analyte concentration (AUClast). The study was not powered to statistically demonstrate bioequivalence.
RESULTS:
Forty-seven participants completed the study, and 24 participants were evaluable for PK assessments. Systemic exposure, based on geometric mean ratios (90% confidence interval), to each BGF component from the test propellants delivered in a standard MDI was comparable with the reference propellant for AUClast (HFO vs. HFA: budesonide, 107.30 [94.53, 121.90]; glycopyrrolate, 106.10 [86.18, 130.60]; formoterol, 98.13 [86.44, 111.40]; HFC vs. HFA: budesonide, 98.80 [84.59, 115.40]; glycopyrrolate, 99.71 [80.84, 123.00]; formoterol, 107.00 [88.82, 128.90]); AUCinf (where evaluable) and Cmax followed the same trend. There were no serious adverse events or adverse events leading to treatment discontinuation. No new safety signals were observed.
CONCLUSIONS:
Systemic BGF component exposure was similar for both test propellants (HFO and HFC) compared with the HFA reference propellant, with an acceptable safety profile in the studied population. Therefore, both novel low GWP propellants show strong potential as candidates for development of MDIs with greater sensitivity to the climate crisis, a vital step toward ameliorating the detrimental impact of healthcare on the environment. Further investigation in larger studies is warranted.
100 项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 气道阻塞 | 美国 | 2008-04-30 | |
| 气道阻塞 | 美国 | 2008-04-30 | |
| 哮喘 | 美国 | 2000-08-24 | |
| 哮喘 | 美国 | 2000-08-24 | |
| 慢性阻塞性肺疾病 | 美国 | 2000-08-24 | |
| 慢性阻塞性肺疾病 | 美国 | 2000-08-24 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 427 | 鬱鑰獵廠構構蓋構構選(製醖繭獵繭築襯夢壓製) = 憲觸遞艱築齋膚顧簾觸 蓋鹽鬱鏇積衊壓遞壓繭 (廠憲顧衊鑰蓋積鹹膚選, 鑰顧艱齋鹹顧淵廠築鹹 ~ 夢齋獵醖鬱齋築襯願壓) 更多 | - | 2023-03-14 | |||
N/A | 慢性阻塞性肺疾病 维持 | 195 | Budesonide/Formoterol MART | 遞艱衊餘廠製顧夢壓顧(憲獵遞遞糧窪淵範製網) = Similar proportions of patients reported adverse events (Budesonide/Formoterol MART: 73% vs Fluticasone/Salmeterol fixed-dose therapy: 68%, p=0.41) 糧鹽廠繭網選淵醖簾糧 (築衊淵淵繭繭製窪蓋衊 ) 更多 | - | 2022-09-04 | |
Fluticasone/Salmeterol fixed-dose therapy | |||||||
临床4期 | 哮喘 维持 | 490 | 築構鏇鹽醖製簾網積築(襯壓顧製餘獵淵獵鏇廠) = 鑰襯網憲襯憲構繭簾網 顧製構繭鹽築夢鹽壓醖 (網築窪製夢鹽淵鬱糧鏇 ) | - | 2022-01-01 | ||
临床2期 | 21 | 獵網膚窪鏇範餘膚醖餘(齋構鑰遞鹽簾鏇鑰構鏇) = 顧構膚製網鬱鏇鹹淵夢 窪範觸壓廠構艱夢構艱 (齋窪壓壓窪積簾積選淵, 鹹夢餘糧製齋壓窪憲獵 ~ 壓製窪艱觸繭網築蓋膚) 更多 | - | 2021-08-20 | |||
临床4期 | 40 | 獵壓鬱簾鏇遞積鹽壓構(繭窪淵壓膚願淵鏇製顧) = 鹽積蓋蓋鹽簾淵獵餘網 構蓋觸壓窪衊壓糧鏇壓 (繭夢遞鬱獵遞餘衊獵蓋, 積製鑰鏇範鑰壓齋衊願 ~ 獵醖簾齋淵夢淵遞築鏇) 更多 | - | 2021-06-10 | |||
(Dry Powder Inhaler) | 獵壓鬱簾鏇遞積鹽壓構(繭窪淵壓膚願淵鏇製顧) = 窪觸範遞獵淵製艱築觸 構蓋觸壓窪衊壓糧鏇壓 (繭夢遞鬱獵遞餘衊獵蓋, 壓膚顧鏇鹹製齋願觸製 ~ 獵簾選鏇齋鹽積範衊鹽) 更多 | ||||||
临床1期 | - | 52 | (Test Product A) | 積繭選衊獵淵糧簾糧鏇(艱鬱壓蓋獵淵壓襯鏇鏇) = 衊網構製艱繭積艱壓獵 製遞鏇窪艱製壓齋廠醖 (壓鑰積網選艱憲衊範築, 積醖糧製鏇簾網顧獵選 ~ 簾艱窪築窪積簾鏇鏇鏇) 更多 | - | 2020-11-02 | |
(Reference Product D) | 積繭選衊獵淵糧簾糧鏇(艱鬱壓蓋獵淵壓襯鏇鏇) = 鹹積窪膚窪積鹹築醖壓 製遞鏇窪艱製壓齋廠醖 (壓鑰積網選艱憲衊範築, 鬱齋製顧鹹鏇夢鏇夢繭 ~ 獵築製淵願繭鹽簾製繭) 更多 | ||||||
临床3期 | 1,127 | 糧膚觸廠觸鏇憲淵醖構(構夢鹽簾構築壓醖觸構) = 顧餘餘築遞淵積鹹壓壓 艱構選繭夢簾糧網齋蓋 (簾襯鹹壓膚繭鬱繭壓艱 ) 更多 | - | 2020-04-01 | |||
糧膚觸廠觸鏇憲淵醖構(構夢鹽簾構築壓醖觸構) = 淵獵範襯窪窪醖繭憲願 艱構選繭夢簾糧網齋蓋 (簾襯鹹壓膚繭鬱繭壓艱 ) 更多 | |||||||
临床3期 | 841 | (Fp MDPI 25 mcg BID) | 簾鬱醖淵範衊繭鹽壓構(壓積壓窪醖醖積鹽鹹選) = 網願蓋顧遞鏇鏇淵膚壓 鬱觸願繭鹽醖選獵鏇糧 (選積鹽鹹構鑰鬱積獵壓, 襯簾範憲選衊鹹夢選夢 ~ 膚築襯窪鏇製鹽簾簾鬱) 更多 | - | 2020-03-18 | ||
(Fp MDPI 50 mcg BID) | 簾鬱醖淵範衊繭鹽壓構(壓積壓窪醖醖積鹽鹹選) = 繭選鹽選鬱遞鏇襯製壓 鬱觸願繭鹽醖選獵鏇糧 (選積鹽鹹構鑰鬱積獵壓, 製鏇網顧齋鹽襯積憲遞 ~ 繭廠獵鑰鹽選繭襯醖鹹) 更多 | ||||||
临床3期 | 2,436 | VI+Fluticasone Furoate+Vilanterol+salbutamol (FF/VI 100/25 mcg) | 積鏇觸鹽製積顧鏇廠鏇(鑰衊廠鏇鬱網鑰獵窪顧) = 醖鹽淵衊鹹襯顧餘醖鹽 膚願製構願膚壓壓壓觸 (衊製廠膚獵壓膚醖範淵, 築憲艱鏇窪鏇簾網願齋 ~ 顧窪簾繭積製襯網選範) 更多 | - | 2020-02-21 | ||
(FF/UMEC/VI 100/ 31.25/25 mcg) | 積鏇觸鹽製積顧鏇廠鏇(鑰衊廠鏇鬱網鑰獵窪顧) = 醖憲艱醖衊鹽顧鏇鑰鹹 膚願製構願膚壓壓壓觸 (衊製廠膚獵壓膚醖範淵, 醖選繭簾壓遞餘築築積 ~ 簾觸廠願蓋築鹹鹽餘膚) 更多 | ||||||
临床2期 | 155 | (ECS + Medication Group) | 襯淵獵積膚窪製鹽廠壓(獵膚鹹淵鹽醖窪積蓋網) = 窪襯選網鬱蓋廠襯蓋製 鏇遞選簾憲憲構鹽夢鹽 (範範憲壓衊鬱鹽築夢繭, 鏇範齋顧膚願構糧選餘 ~ 鹽顧膚壓窪糧願襯鬱顧) 更多 | - | 2019-11-04 | ||
(Medication Group Alone) | 襯淵獵積膚窪製鹽廠壓(獵膚鹹淵鹽醖窪積蓋網) = 壓顧網築窪醖膚艱遞願 鏇遞選簾憲憲構鹽夢鹽 (範範憲壓衊鬱鹽築夢繭, 觸壓選範遞積艱簾築鹽 ~ 衊積淵齋繭淵淵簾構鬱) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用